EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Epithelial–mesenchymal plasticity in kidney fibrosis

Sudarat Hadpech, Visith Thongboonkerd iD

genesis · 2024-02 · 62 (1)

DOI: 10.1002/dvg.23529 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift genesis, online erschienen am 22.06.2023. Verfasst von Sudarat Hadpech und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medical Proteomics Unit, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Transforming Growth Factor beta1, beta Catenin. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 175 Literaturangaben. Gefördert von: National Research Council of Thailand, Mahidol University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epithelial–mesenchymal transition (EMT) is an important biological process contributing to kidney fibrosis and chronic kidney disease. This process is characterized by decreased epithelial phenotypes/markers and increased mesenchymal phenotypes/markers. Tubular epithelial cells (TECs) are commonly susceptible to EMT by various stimuli, for example, transforming growth factor‐β (TGF‐β), cellular communication network factor 2, angiotensin‐II, fibroblast growth factor‐2, oncostatin M, matrix metalloproteinase‐2, tissue plasminogen activator (t‐PA), plasmin, interleukin‐1β, and reactive oxygen species. Similarly, glomerular podocytes can undergo EMT via these stimuli and by high glucose condition in diabetic kidney disease. EMT of TECs and podocytes leads to tubulointerstitial fibrosis and glomerulosclerosis, respectively. Signaling pathways involved in EMT‐mediated kidney fibrosis are diverse and complex. TGF‐β1/Smad and Wnt/β‐catenin pathways are the major venues triggering EMT in TECs and podocytes. These two pathways thus serve as the major therapeutic targets against EMT‐mediated kidney fibrosis. To date, a number of EMT inhibitors have been identified and characterized. As expected, the majority of these EMT inhibitors affect TGF‐β1/Smad and Wnt/β‐catenin pathways. In addition to kidney fibrosis, these EMT‐targeted antifibrotic inhibitors are expected to be effective for treatment against fibrosis in other organs/tissues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transforming Growth Factor beta1beta CateninHumansMatrix Metalloproteinase 2Tissue Plasminogen ActivatorEpithelial CellsWnt Signaling PathwayEpithelial-Mesenchymal TransitionKidneyFibrosis

Stichwörter der Autor:innen

CKDEMTantifibroticglomerulosclerosisinhibitorspodocyterenal fibrosis

Substanzen

Transforming Growth Factor beta1beta CateninMatrix Metalloproteinase 2Tissue Plasminogen Activator

Autor:innen und Institutionen

  • Medical Proteomics Unit, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

ORCID-Profile: Visith Thongboonkerd

Förderung

  • National Research Council of Thailand
  • Mahidol University

Zitieren

APA

Hadpech, S., & Thongboonkerd, V. (2024). Epithelial–mesenchymal plasticity in kidney fibrosis. genesis, 62(1). https://doi.org/10.1002/dvg.23529

Vancouver

Hadpech S, Thongboonkerd V. Epithelial–mesenchymal plasticity in kidney fibrosis. genesis. 2024;62(1). doi:10.1002/dvg.23529

BibTeX
@article{Hadpech2024,
  author = {Hadpech, Sudarat and Thongboonkerd, Visith},
  title = {Epithelial–mesenchymal plasticity in kidney fibrosis},
  journal = {genesis},
  year = {2024},
  volume = {62},
  number = {1},
  doi = {10.1002/dvg.23529}
}
Kostenlos starten →